Financials
| Half-year Report | Sep. 26, 2024 |
| Posting of 2023 Annual Report & Notice of the AGM | Jun. 18, 2024 |
| Preliminary Results | Jun. 05, 2024 |
| Trading and business update | Nov. 09, 2023 |
| Interim Results for the period ended 30 June 2023 | Sep. 07, 2023 |
| Results for the year ended 31 December 2022 | Apr. 21, 2023 |
| Interim Results | Sep. 29, 2022 |
Proxies
| Result of 2024 Annual General Meeting | Jul. 11, 2024 |
| Result of 2023 Annual General Meeting | Jun. 28, 2023 |
| Result of 2022 Annual General Meeting | Jun. 29, 2022 |
| Result of AGM | Jun. 30, 2021 |
| Annual General Meeting update | Jun. 18, 2021 |
| Result of 2020 Annual General Meeting | Aug. 27, 2020 |
| Notice of AGM and Posting of Annual Report | Aug. 05, 2020 |
Ownership Update
| Standard form for notification of major holdings | Jul. 18, 2024 |
| Standard form for notification of major holdings | Jul. 12, 2024 |
| Standard form for notification of major holdings | Jan. 10, 2024 |
| Standard form for notification of major holdings | Jun. 27, 2023 |
| Issue of LTIP Options and Share Options | Mar. 10, 2023 |
| Holding(s) in Company | Mar. 09, 2023 |
| Holding(s) in Company | Jan. 11, 2023 |
Announcements
| HER2 presentation at SABCS | Dec. 13, 2024 |
| Parsortix based PD-L1 assay showcased at AACR | Nov. 15, 2024 |
| Research on HER2 assay kit showcased at AACR | Nov. 15, 2024 |
| ANGLE presents two posters at EACR | Nov. 13, 2024 |
| Parsortix enriched CTC & ctDNA in NSCLC patients | Nov. 11, 2024 |
| Publication demonstrates CTC profiling potential | Oct. 17, 2024 |
| 100th publication supporting Parsortix system use | Sep. 26, 2024 |